An entrepreneurial and human adventure
More than 20 years of experience and continuous growth
1998:
<p>Foundation of Provence Technologies, a <strong>research and development chemistry laboratory</strong>, resulting from the association of the 2 founding partners: Michel FERAUD and Christophe BARALOTTO. The company operates as a subcontractor for biotechnological companies and international pharmaceutical groups. The company thus builds its reputation in different fields such as pharmaceuticals, cosmetics and agrochemicals.</p>
SINCE 2003:
<p>Given its solid financial structure, Provence Technologies launches several internal research programs. One of them concerns a new process for the synthesis of methylene blue, which led to <strong>the filing of a international patent in 2006.</strong> A year later, in 2007, Provepharm, a subsidiary of Provence Technologies, was founded to develop and commercialize this product.</p>
2011:
<p><strong>Obtains a Centralized Marketing Authorization</strong> paving the way for the commercialization of Proveblue<sup>®</sup> in the 30 countries of the enlarged European Union: the authorities recognize patient benefit of Proveblue<sup>®</sup>.</p> <p>Thus, Michel FERAUD, co-inventor with Babak SAYAH of this patent, also becomes President and builds a team of professionals as well as a committee of internationally renowned experts.</p>
2014:
<p>The group acquires a company specialized in the<strong>chemical synthesis of peptides and proteins for therapeutic use.</strong> This operation opens a new development path for the company in the field of biological pharmaceutical products.</p>
2016:
<p>An important milestone is reached: Provepharm <strong>obtains FDA approval </strong>to commercialize ProvayBlue<sup>™</sup>, its Injectable Methylene Blue.</p>
2017:
<p>The company becomes <strong>Provepharm Life Solutions</strong> and launches its new brand identity. The adventure continues!</p>
2018:
<p>Provepharm Life Solutions joins forces with <strong>new strategic partners</strong>, <a href="https://www.archimed.fr/" rel="noopener" target="_blank">A</a><a href="http://www.archimed-group.eu/" rel="noopener" target="_blank">rchiMed</a> et <a href="https://www.tethysinvestments.com/" rel="noopener" target="_blank">Téthys Invest</a>.</p>